http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 08 Sep 2026 09:16:19 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Akari+Therapeutics+to+present+ADC+platform+at+five+September+conferences/27034409.html <p>Akari Therapeutics, Plc (Nasdaq: AKTX) announced it has been selected to present at five oncology, ADC, and healthcare conferences in the United States and China during September 2026, according to a company statement.</p><p>President and CEO Abizer Gaslightwala will represent the company across the events, which include the Oncology & Immunology Innovation Partnering & Licensing Summit in Boston (Sept. 9–10), BioCon China 2026 in Shanghai (Sept. 15–16), the 2026 Global XDC Innovation Conference in Wuxi, China (Sept. 17–19), the H.C. Wainwright 28th Annual Global Investment Conference in New York (Sept. 14–16), and the 5th Annual ROTH Healthcare Opportunities Conference in New http://www.streetinsider.com/Corporate+News/Akari+Therapeutics+to+present+ADC+platform+at+five+September+conferences/27034409.html Tue, 08 Sep 2026 09:16:19 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Selected+to+Showcase+Novel+PH1+ADC+Payload+Platform+at+Leading+Global+Oncology%2C+ADC+and+Healthcare+Forums/27034376.html <p align="center"><em>Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September</em></p> <p align="center"><em>CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations </em></p> <p align="justify">TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Selected+to+Showcase+Novel+PH1+ADC+Payload+Platform+at+Leading+Global+Oncology%2C+ADC+and+Healthcare+Forums/27034376.html Tue, 08 Sep 2026 09:15:00 -0400 AKTX http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Selected+to+Showcase+Novel+PH1+ADC+Payload+Platform+at+Leading+Global+Oncology%2C+ADC+and+Healthcare+Forums/27034376.html <p align="center"><em>Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September</em></p> <p align="center"><em>CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations </em></p> <p align="justify">TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Selected+to+Showcase+Novel+PH1+ADC+Payload+Platform+at+Leading+Global+Oncology%2C+ADC+and+Healthcare+Forums/27034376.html Tue, 08 Sep 2026 09:15:00 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985907.html <p align="center"><em>Video webcast now available </em><a href="https://www.globenewswire.com/Tracker?data=6Vnw6sEbN8pwtVfsrvI30C3blSixxxmE6PJY1bYILg1uZq4LQqQ3bkDBIsv3T7QXIXIkpcaSbyHQbbSmpH6cemigIj4foMAhOBq05K4XibU=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the <a href="https://www.globenewswire.com/Tracker?data=3SUa2fqGfk34l2ZCO8JJqJkzD_h2ewPgDU5IczvDNA4wwFfgaxNKDmdT56SQ8l-i6EgK79V3-duK8GoaU1wvrFtXDSVCMi1DqVoz9g5SqEADJMg-oPU2z_nuA6xizfzVPejo-TMvRvHCABU2M9LH1w==" rel="nofollow" target="_blank">Virtual Investor "Why Now" on-demand conference</a>.</p> <p align="justify">During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company's investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing industry demand http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985907.html Thu, 27 Aug 2026 09:01:00 -0400 AKTX http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985907.html <p align="center"><em>Video webcast now available </em><a href="https://www.globenewswire.com/Tracker?data=6Vnw6sEbN8pwtVfsrvI30C3blSixxxmE6PJY1bYILg1uZq4LQqQ3bkDBIsv3T7QXIXIkpcaSbyHQbbSmpH6cemigIj4foMAhOBq05K4XibU=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the <a href="https://www.globenewswire.com/Tracker?data=3SUa2fqGfk34l2ZCO8JJqJkzD_h2ewPgDU5IczvDNA4wwFfgaxNKDmdT56SQ8l-i6EgK79V3-duK8GoaU1wvrFtXDSVCMi1DqVoz9g5SqEADJMg-oPU2z_nuA6xizfzVPejo-TMvRvHCABU2M9LH1w==" rel="nofollow" target="_blank">Virtual Investor "Why Now" on-demand conference</a>.</p> <p align="justify">During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company's investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing industry demand http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985907.html Thu, 27 Aug 2026 09:01:00 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=6Vnw6sEbN8pwtVfsrvI30C3blSixxxmE6PJY1bYILg1uZq4LQqQ3bkDBIsv3T7QXIXIkpcaSbyHQbbSmpH6cemigIj4foMAhOBq05K4XibU=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3SUa2fqGfk34l2ZCO8JJqJkzD_h2ewPgDU5IczvDNA4wwFfgaxNKDmdT56SQ8l-i6EgK79V3-duK8GoaU1wvrFtXDSVCMi1DqVoz9g5SqEADJMg-oPU2z_nuA6xizfzVPejo-TMvRvHCABU2M9LH1w==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company&apos;s investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html Thu, 27 Aug 2026 09:01:00 -0400 AKTX O.01517653 http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=6Vnw6sEbN8pwtVfsrvI30C3blSixxxmE6PJY1bYILg1uZq4LQqQ3bkDBIsv3T7QXIXIkpcaSbyHQbbSmpH6cemigIj4foMAhOBq05K4XibU=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3SUa2fqGfk34l2ZCO8JJqJkzD_h2ewPgDU5IczvDNA4wwFfgaxNKDmdT56SQ8l-i6EgK79V3-duK8GoaU1wvrFtXDSVCMi1DqVoz9g5SqEADJMg-oPU2z_nuA6xizfzVPejo-TMvRvHCABU2M9LH1w==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company&apos;s investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html Thu, 27 Aug 2026 09:01:00 -0400 AKTX O.01517653 http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=6Vnw6sEbN8pwtVfsrvI30C3blSixxxmE6PJY1bYILg1uZq4LQqQ3bkDBIsv3T7QXIXIkpcaSbyHQbbSmpH6cemigIj4foMAhOBq05K4XibU=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3SUa2fqGfk34l2ZCO8JJqJkzD_h2ewPgDU5IczvDNA4wwFfgaxNKDmdT56SQ8l-i6EgK79V3-duK8GoaU1wvrFtXDSVCMi1DqVoz9g5SqEADJMg-oPU2z_nuA6xizfzVPejo-TMvRvHCABU2M9LH1w==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company&apos;s investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html Thu, 27 Aug 2026 09:01:00 -0400 AKTX O.01517653 http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=6Vnw6sEbN8pwtVfsrvI30C3blSixxxmE6PJY1bYILg1uZq4LQqQ3bkDBIsv3T7QXIXIkpcaSbyHQbbSmpH6cemigIj4foMAhOBq05K4XibU=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3SUa2fqGfk34l2ZCO8JJqJkzD_h2ewPgDU5IczvDNA4wwFfgaxNKDmdT56SQ8l-i6EgK79V3-duK8GoaU1wvrFtXDSVCMi1DqVoz9g5SqEADJMg-oPU2z_nuA6xizfzVPejo-TMvRvHCABU2M9LH1w==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company&apos;s investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985921.html Thu, 27 Aug 2026 09:01:00 -0400 AKTX O.01517653 http://www.streetinsider.com/Corporate+News/Akari+Therapeutics+shares+preclinical+data+for+AKTX-101+in+urothelial+cancer/26941341.html <p>Akari Therapeutics, Plc (Nasdaq: AKTX) released preclinical data for its antibody drug conjugate AKTX-101, showing anti-tumor activity across multiple urothelial cancer models, according to a company statement.</p><p>The data showed that AKTX-101, a TROP2-targeted ADC using the company's PH1 RNA spliceosome-modulating payload, demonstrated statistically significant tumor growth inhibition in the UM-UC-14 advanced urothelial carcinoma model, a setting where Padcev (enfortumab vedotin) showed limited responsiveness in the same model.</p><p>In a separate model, tumors that had developed resistance to Trodelvy (sacituzumab govitecan), a first-generation TROP2-directed ADC, showed slowed growth again when treatment was switched to AKTX-101. The company said this suggests resistance in http://www.streetinsider.com/Corporate+News/Akari+Therapeutics+shares+preclinical+data+for+AKTX-101+in+urothelial+cancer/26941341.html Tue, 18 Aug 2026 08:54:33 -0400 AKTX http://www.streetinsider.com/FDA/Akari+Therapeutics+shares+preclinical+data+for+AKTX-101+in+urothelial+cancer/26941341.html <p>Akari Therapeutics, Plc (Nasdaq: AKTX) released preclinical data for its antibody drug conjugate AKTX-101, showing anti-tumor activity across multiple urothelial cancer models, according to a company statement.</p><p>The data showed that AKTX-101, a TROP2-targeted ADC using the company's PH1 RNA spliceosome-modulating payload, demonstrated statistically significant tumor growth inhibition in the UM-UC-14 advanced urothelial carcinoma model, a setting where Padcev (enfortumab vedotin) showed limited responsiveness in the same model.</p><p>In a separate model, tumors that had developed resistance to Trodelvy (sacituzumab govitecan), a first-generation TROP2-directed ADC, showed slowed growth again when treatment was switched to AKTX-101. The company said this suggests resistance in http://www.streetinsider.com/FDA/Akari+Therapeutics+shares+preclinical+data+for+AKTX-101+in+urothelial+cancer/26941341.html Tue, 18 Aug 2026 08:54:33 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Builds+Momentum+for+AKTX-101+with+Compelling+Urothelial+Cancer+Data+Supporting+Differentiated+ADC+Strategy/26941329.html <p align="center"><em>AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models</em></p> <p align="center"><em>Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance</em></p> <p align="center"><em>Results strengthen the rationale for a differentiated ADC sequencing strategy as ADC use expands across oncology and more patients require treatment following relapse </em></p> <p align="center"><em>Akari advancing IND-enabling activities for AKTX-101 toward planned Phase 1 clinical development in mid-2027</em></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Builds+Momentum+for+AKTX-101+with+Compelling+Urothelial+Cancer+Data+Supporting+Differentiated+ADC+Strategy/26941329.html Tue, 18 Aug 2026 08:53:00 -0400 AKTX http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Builds+Momentum+for+AKTX-101+with+Compelling+Urothelial+Cancer+Data+Supporting+Differentiated+ADC+Strategy/26941329.html <p align="center"><em>AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models</em></p> <p align="center"><em>Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance</em></p> <p align="center"><em>Results strengthen the rationale for a differentiated ADC sequencing strategy as ADC use expands across oncology and more patients require treatment following relapse </em></p> <p align="center"><em>Akari advancing IND-enabling activities for AKTX-101 toward planned Phase 1 clinical development in mid-2027</em></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Builds+Momentum+for+AKTX-101+with+Compelling+Urothelial+Cancer+Data+Supporting+Differentiated+ADC+Strategy/26941329.html Tue, 18 Aug 2026 08:53:00 -0400 AKTX http://www.streetinsider.com/FDA/Akari+Therapeutics+posts+Q2+2026+loss+of+%244.8M%2C+raises+%248.6M/26921294.html <p>Akari Therapeutics, Plc (Nasdaq: AKTX) reported a net loss of $4.8 million for the second quarter ending June 30, 2026, compared with a net loss of $1.9 million for the same period in 2025, according to a company press release.</p> <p>Research and development expenses rose to $2.1 million in the quarter, up from $0.7 million in the second quarter of 2025, reflecting expanded manufacturing and development activities for its lead candidate, AKTX-101. General and administrative expenses held steady at $2.5 million year over year.</p> <p>Cash totaled $7.7 million as of June 30, 2026, compared with $5.2 million as of December 31, 2025. http://www.streetinsider.com/FDA/Akari+Therapeutics+posts+Q2+2026+loss+of+%244.8M%2C+raises+%248.6M/26921294.html Thu, 13 Aug 2026 16:15:18 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Progress+of+AKTX-101+Towards+Phase+1+and+Strategic+Collaboration+for+Its+ADC+Payload+Platform/26921255.html <p align="center"><em>AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027</em></p> <p align="center"><em>Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models</em></p> <p align="center"><em>Strategic research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs</em></p> <p align="center"><em>Balance sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic investors<br /><br /></em></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Progress+of+AKTX-101+Towards+Phase+1+and+Strategic+Collaboration+for+Its+ADC+Payload+Platform/26921255.html Thu, 13 Aug 2026 16:15:00 -0400 AKTX http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Progress+of+AKTX-101+Towards+Phase+1+and+Strategic+Collaboration+for+Its+ADC+Payload+Platform/26921255.html <p align="center"><em>AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027</em></p> <p align="center"><em>Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models</em></p> <p align="center"><em>Strategic research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs</em></p> <p align="center"><em>Balance sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic investors<br /><br /></em></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Progress+of+AKTX-101+Towards+Phase+1+and+Strategic+Collaboration+for+Its+ADC+Payload+Platform/26921255.html Thu, 13 Aug 2026 16:15:00 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Releases+CEO+Corner+Highlighting+Strategic+WhiteHawk+Collaboration+and+the+Expanding+Opportunity+for+Dual-Payload+ADC+Innovation/26862577.html <p align="center"><em>Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform</em></p> <p align="center"><em>Access the Akari CEO Corner </em><a href="https://www.globenewswire.com/Tracker?data=n2DxsJXmBTz51VWCaVWfl5u_tos-RqdsdBDv4pyZK3Qz1j5GO400o8Zr8px0l3jeROPtiTQbVeC32lIanx5n_A==" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company believes http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Releases+CEO+Corner+Highlighting+Strategic+WhiteHawk+Collaboration+and+the+Expanding+Opportunity+for+Dual-Payload+ADC+Innovation/26862577.html Tue, 04 Aug 2026 08:50:00 -0400 AKTX http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Releases+CEO+Corner+Highlighting+Strategic+WhiteHawk+Collaboration+and+the+Expanding+Opportunity+for+Dual-Payload+ADC+Innovation/26862577.html <p align="center"><em>Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform</em></p> <p align="center"><em>Access the Akari CEO Corner </em><a href="https://www.globenewswire.com/Tracker?data=n2DxsJXmBTz51VWCaVWfl5u_tos-RqdsdBDv4pyZK3Qz1j5GO400o8Zr8px0l3jeROPtiTQbVeC32lIanx5n_A==" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company believes http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Releases+CEO+Corner+Highlighting+Strategic+WhiteHawk+Collaboration+and+the+Expanding+Opportunity+for+Dual-Payload+ADC+Innovation/26862577.html Tue, 04 Aug 2026 08:50:00 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+CEO+Explains+Why+Growing+Industry+Demand+for+Next-Generation+ADC+Payloads+Positions+the+Company+at+the+Center+of+a+Major+Oncology+Opportunity/26798900.html <p align="center"><em>Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform</em></p> <p align="center"><em>Watch the “What This Means” video </em><a href="https://www.globenewswire.com/Tracker?data=3FWLgqwqQuimKWymdl0X02Wkt2VSSURFzmWktQEx-Dnij00cJxgG5588GyioLgtAP_gFNN8S0Z7w8offZzpheEEy_3uYvPw_pT8egL_Tzl4=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, July 22, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today that announced that its CEO, Abizer Gaslightwala, participated in a Virtual Investor "What This Means" interview focused on the Company's <a href="https://www.globenewswire.com/Tracker?data=vRnGQPeLoSuRYF9lhi7X-_s4tYiuNZWFYjpaLL57FJYprFP1QAd1UNBHGGPMaP8ykWTm2wi-EhFrhROA-VNBE0XBLGQIkqhcvApUtPH1_VQVe9iPBI8h9ifIVbnToVHBQFnFt3WY_JxZ91UQdw5DY7xLi03czSbGklHOvFl-uoO3Z4UUT5DlA34xKlv8t5p_q5b03fYluAvIqyKGtx014Pl7ac6OK5_Nqxndk-y4I-h7sIDBX-cpDOCk_0Nz9EcXpKryCLsp4_02iCzNmn9sXEXdriedliIh-Zbei8J4V8WSgfmEFBY5p9rLTeCC4d_B" rel="nofollow" target="_blank">recently announced strategic research collaboration with Whitehawk http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+CEO+Explains+Why+Growing+Industry+Demand+for+Next-Generation+ADC+Payloads+Positions+the+Company+at+the+Center+of+a+Major+Oncology+Opportunity/26798900.html Wed, 22 Jul 2026 08:40:00 -0400 AKTX http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+CEO+Explains+Why+Growing+Industry+Demand+for+Next-Generation+ADC+Payloads+Positions+the+Company+at+the+Center+of+a+Major+Oncology+Opportunity/26798900.html <p align="center"><em>Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform</em></p> <p align="center"><em>Watch the “What This Means” video </em><a href="https://www.globenewswire.com/Tracker?data=3FWLgqwqQuimKWymdl0X02Wkt2VSSURFzmWktQEx-Dnij00cJxgG5588GyioLgtAP_gFNN8S0Z7w8offZzpheEEy_3uYvPw_pT8egL_Tzl4=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">TAMPA, Fla. and LONDON, July 22, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today that announced that its CEO, Abizer Gaslightwala, participated in a Virtual Investor "What This Means" interview focused on the Company's <a href="https://www.globenewswire.com/Tracker?data=vRnGQPeLoSuRYF9lhi7X-_s4tYiuNZWFYjpaLL57FJYprFP1QAd1UNBHGGPMaP8ykWTm2wi-EhFrhROA-VNBE0XBLGQIkqhcvApUtPH1_VQVe9iPBI8h9ifIVbnToVHBQFnFt3WY_JxZ91UQdw5DY7xLi03czSbGklHOvFl-uoO3Z4UUT5DlA34xKlv8t5p_q5b03fYluAvIqyKGtx014Pl7ac6OK5_Nqxndk-y4I-h7sIDBX-cpDOCk_0Nz9EcXpKryCLsp4_02iCzNmn9sXEXdriedliIh-Zbei8J4V8WSgfmEFBY5p9rLTeCC4d_B" rel="nofollow" target="_blank">recently announced strategic research collaboration with Whitehawk http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+CEO+Explains+Why+Growing+Industry+Demand+for+Next-Generation+ADC+Payloads+Positions+the+Company+at+the+Center+of+a+Major+Oncology+Opportunity/26798900.html Wed, 22 Jul 2026 08:40:00 -0400 AKTX http://www.streetinsider.com/Corporate+News/Akari+Therapeutics+enters+ADC+research+deal+with+Whitehawk+Therapeutics/26792068.html <p>Akari Therapeutics, Plc (NASDAQ: AKTX) announced a research collaboration with Whitehawk Therapeutics to conduct preclinical studies combining Akari's PH1 spliceosome-modulating payload technology with Whitehawk's topoisomerase I inhibitor (TOP1i) antibody drug conjugate (ADC) platform.</p><p>Under the agreement, Akari will lead the design, execution, and evaluation of research activities. The initial collaboration will include multiple preclinical workstreams aimed at assessing dual payload compatibility and generating data to guide future development decisions.</p><p>The collaboration is expected to begin immediately, with interim data updates anticipated as studies progress. Both companies will jointly review resulting data to determine whether findings support broader development discussions.</p><p>Abizer Gaslightwala, President and http://www.streetinsider.com/Corporate+News/Akari+Therapeutics+enters+ADC+research+deal+with+Whitehawk+Therapeutics/26792068.html Tue, 21 Jul 2026 07:05:50 -0400 AKTX http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Enters+Strategic+Research+Collaboration+with+Whitehawk+Therapeutics/26792054.html <p><strong>Collaboration will evaluate Akari&apos;s PH1 payload technology in combination with Whitehawk&apos;s TOP1i payload to generate potential future development opportunities</strong></p><p align="justify">TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination http://www.streetinsider.com/Press+Releases/Akari+Therapeutics+Enters+Strategic+Research+Collaboration+with+Whitehawk+Therapeutics/26792054.html Tue, 21 Jul 2026 07:05:00 -0400 AKTX http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Enters+Strategic+Research+Collaboration+with+Whitehawk+Therapeutics/26792054.html <p><strong>Collaboration will evaluate Akari&apos;s PH1 payload technology in combination with Whitehawk&apos;s TOP1i payload to generate potential future development opportunities</strong></p><p align="justify">TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination http://www.streetinsider.com/Globe+Newswire/Akari+Therapeutics+Enters+Strategic+Research+Collaboration+with+Whitehawk+Therapeutics/26792054.html Tue, 21 Jul 2026 07:05:00 -0400 AKTX http://www.streetinsider.com/Upgrades/Maxim+Group+Upgrades+Akari+Therapeutics+%28AKTX%29+to+Buy/26787088.html <p>Maxim Group analyst Jason McCarthy upgraded Akari Therapeutics (NASDAQ: AKTX) from Hold to Buy with a price target of $30.00.</p><p>For an analyst ratings summary and ratings history on Akari Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=AKTX">click here</a>. For more ratings news on Akari Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AKTX&amp;type=analyst">click here</a>.</p><p>Shares of Akari Therapeutics closed at $11.01 yesterday.</p> http://www.streetinsider.com/Upgrades/Maxim+Group+Upgrades+Akari+Therapeutics+%28AKTX%29+to+Buy/26787088.html Mon, 20 Jul 2026 07:34:17 -0400 AKTX http://www.streetinsider.com/Board+Changes/Akari+Therapeutics+adds+oncology+expert+Patricia+LoRusso+to+advisory+board/26739380.html <p>Akari Therapeutics, Plc (NASDAQ: AKTX) announced the appointment of Patricia LoRusso, D.O., to its Scientific Advisory Board, according to a company press release dated July 7, 2026.</p> <p>Dr. LoRusso currently serves as the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, where she also holds the roles of Chief of Experimental Therapeutics and Associate Cancer Center Director of Experimental Therapeutics. She previously held leadership positions at Wayne State University's Barbara Karmanos Cancer Institute, including Director of the Phase I Clinical Trials Program.</p> <p>She is a past president of the American Association for Cancer Research (AACR) and has served as http://www.streetinsider.com/Board+Changes/Akari+Therapeutics+adds+oncology+expert+Patricia+LoRusso+to+advisory+board/26739380.html Tue, 07 Jul 2026 08:55:14 -0400 AKTX